Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment With Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy

NCT02516423 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT02516423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02516423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment With Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Terminated
Start date
November 29, 2016
Completion date
September 30, 2025
Enrollment
11 (actual)
Sites
388

Conditions

As the registry lists them; a condition with its own page is linked.

solitary osseous plasmacytoma